Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.4.53 - 3',5'-cyclic-AMP phosphodiesterase and Organism(s) Homo sapiens and UniProt Accession Q08499

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
3',5'-cyclic-amp phosphodiesterase deficiency
Cardiac Overexpression of PDE4B Blunts ?-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.
Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice.
Acquired Immunodeficiency Syndrome
Novel GFP-fused protein probes for detecting phosphatidylinositol-4-phosphate in the plasma membrane.
Acute Kidney Injury
Rutaecarpine derivative Cpd-6c alleviates acute kidney injury by targeting PDE4B, a key enzyme mediating inflammation in cisplatin nephropathy.
Acute Lung Injury
Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.
Additive effects of phosphodiesterase-4 inhibition on effects of rSP-C surfactant.
Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on the lung functions in a saline lavage-induced model of acute lung injury.
Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study.
Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between Tumor necrosis factor-alpha and interleukin-10.
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury.
Adenocarcinoma, Follicular
Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.
Adenoma
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.
Airway Obstruction
In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.
Alcoholic Neuropathy
Electrophysiological and behavioral changes by phosphodiesterase 4 inhibitor in a rat model of alcoholic neuropathy.
Alopecia Areata
Development of alopecia areata during phosphodiesterase 4 inhibitor treatment for psoriasis: A case report.
Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
Alzheimer Disease
A Hypothesis and Evidence That Mercury May be an Etiological Factor in Alzheimer's Disease.
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
Etazolate improves performance in a foraging and homing task in aged rats.
FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
Increased isoform-specific phosphodiesterase 4D expression is associated with pathology and cognitive impairment in Alzheimer's disease.
Inverse Molecular Docking as a Novel Approach to Study Anticarcinogenic and Anti-Neuroinflammatory Effects of Curcumin.
Phosphodiesterase 4D Gene Modifies the Functional Network of Patients With Mild Cognitive Impairment and Alzheimer's Disease.
Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease.
Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
Phosphodiesterase-4D Knockdown in the Prefrontal Cortex Alleviates Memory Deficits and Synaptic Failure in Mouse Model of Alzheimer's Disease.
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer's disease: a preclinical study in APP/PS1 transgenic mice.
Amnesia
Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents.
Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats.
Anaphylaxis
An isoenzyme-selective inhibitor of phosphodiesterase 4 and 1, KF19514, may be useful in the treatment of systemic anaphylaxis: an in vivo study in rabbits.
Anhedonia
Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.
Aortic Aneurysm, Abdominal
Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA.
Apnea
Reversal by phosphodiesterase-4 blockers of in vitro apnea in the isolated brainstem-spinal cord preparation from newborn rats.
Arrhythmias, Cardiac
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arthritis
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.
Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Psoriatic Arthritis: Newer and Older Therapies.
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Arthritis, Experimental
Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Arthritis, Juvenile
The autonomic nervous system and the immune system in juvenile rheumatoid arthritis.
Arthritis, Psoriatic
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B.
Apremilast for psoriasis treatment.
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
Apremilast in Refractory Alopecia Areata.
Apremilast in the Management of Disseminated Granuloma Annulare.
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.
Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Crystal structure of an apremilast ethanol hemisolvate hemihydrate solvatomorph.
Drug survival of apremilast in a real-world setting.
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Emerging drugs for psoriatic arthritis.
Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice.
IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis.
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis.
Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Off-label studies on apremilast in dermatology: a review.
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study.
PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1.
Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
Refractory palmoplantar pustulosis succesfully treated with apremilast.
Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
The Protective Effects of Apremilast Against Oxygen-Glucose Deprivation/Reperfusion (OGD/R)-Induced Inflammation and Apoptosis in Astroglia Mediated by CREB/BDNF.
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Work Productivity Improvement Associated With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results Of A Phase 3, Randomized, Controlled Trial.
[Gastrointestinal side effects of apremilast : Characterization and management].
Arthritis, Rheumatoid
3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
[3',5'-cAMP phosphodiesterase inhibitors in the combined treatment of patients with rheumatoid arthritis]
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Asthma
(P)/(M)-corinepalensin A, a pair of axially chiral prenylated bicoumarin enantiomers with a rare C-5C-5' linkage from the twigs of Coriaria nepalensis.
3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.
?2-Agonists upregulate PDE4 mRNA but not protein or activity in human airway smooth muscle cells from asthmatic and nonasthmatic volunteers.
A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma.
A Novel Heterodimer from Crotalaria ferruginea.
Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats.
Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Analyses of shared genetic factors between asthma and obesity in children.
Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.
CC-10004 .
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.
Constitutively Active Signaling by the G Protein ??-Subunit Mediates Intrinsically Increased Phosphodiesterase-4 Activity in Human Asthmatic Airway Smooth Muscle Cells.
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Current and emerging therapies for the management of chronic inflammation in asthma.
Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study.
Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor.
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Effects of inhaled glaucine on pulmonary responses to antigen in sensitized guinea pigs.
Effects of KF19514, a Phosphodiesterase 4 and 1 Inhibitor, on Bronchial Inflammation and Remodeling in a Murine Model of Chronic Asthma.
Effects of phosphodiesterase 4 inhibitor on cough response in guinea pigs sensitized and challenged with ovalbumin.
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis.
Efficacy and safety of roflumilast in the treatment of asthma.
Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
Electrochemical Behavior and Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms.
Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene.
Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor.
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.
Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages.
Investigating the role of N-terminal domain in phosphodiesterase 4B-inhibition by molecular dynamics simulation.
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Lysoquinone-TH1, a New Polyphenolic Tridecaketide Produced by Expressing the Lysolipin Minimal PKS II in Streptomyces albus.
Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.
Natural phosphodiesterase-4 (PDE4) inhibitors from Crotalaria ferruginea.
New advances and potential therapies for the treatment of asthma.
Novel signal transduction modulators for the treatment of airway diseases.
Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Pharmacology of a novel, orally active PDE4 inhibitor.
Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors.
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma.
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by ?2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice.
Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
Phosphodiesterase 4B is essential for T(h)2-cell function and development of airway hyperresponsiveness in allergic asthma.
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor.
Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from Toddalia asiatica.
Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
Production and characterization of pharmacologically active recombinant human phosphodiesterase 4B in Dictyostelium discoideum.
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.
Psiguajadials A-K: Unusual Psidium Meroterpenoids as Phosphodiesterase-4 Inhibitors from the Leaves of Psidium guajava.
PTTG1IP and MAML3, novel genomewide association study genes for severity of hyperresponsiveness in adult asthma.
Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
Selaginpulvilins A-D, new phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella pulvinata.
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Single-dose pharmacokinetics of roflumilast in children and adolescents.
Structure Based Design of Selective Phosphodiesterase 4B Inhibitors Based on Ginger Phenolic Compounds.
Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.
Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma.
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs.
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys.
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
Treating asthma in the new millennium.
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Upregulation of phosphodiesterase-4 in the lung of allergic rats.
Asthma, Exercise-Induced
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
Atherosclerosis
Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.
Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke.
Phosphodiesterase 4D Single Nucleotide Polymorphism 83 and Cognitive Dysfunction in Carotid Endarterectomy Patients.
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Autoimmune Diseases
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.
Axial Spondyloarthritis
Axial spondyloarthritis: is there a treatment of choice?
Behcet Syndrome
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Apremilast in the Management of Disseminated Granuloma Annulare.
Bone Diseases, Metabolic
Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models.
Bone Resorption
Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
Brain Diseases
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET.
Brain Edema
Decreased adenosine cyclic 3',5'-monophosphate phosphodiesterase activity in rat brain following triethyltin intoxication.
Brain Injuries
Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders.
Improved sensorimotor function by rolipram following focal cerebral ischemia in rats.
Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway.
Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
Brain Injuries, Traumatic
Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
Tumor Necrosis Factor ? as a Potential Mediator of the Effects of Phosphodiesterase 4B Inhibition on Cognition after Traumatic Brain Injury.
Brain Ischemia
Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2/HO-1 pathway.
Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3?-mediated oxidative stress and IRE1?/TRAF2/JNK pathway.
Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia.
Brain Neoplasms
Phosphodiesterase-4 inhibition and brain tumor growth.
Targeted activation of PKA and Epac promotes glioblastoma regression in vitro.
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Breast Neoplasms
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility.
Bronchial Spasm
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
Bronchiolitis
Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts.
Bronchitis, Chronic
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation.
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.
Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study.
Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences.
The clinical and economic burden of chronic obstructive pulmonary disease in the USA.
Carcinogenesis
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.
Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines.
Carcinoma
7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells.
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway.
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
Triazole-Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells.
Carcinoma, Hepatocellular
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
[Concentration and metabolism of cyclic AMP during the early stages of hepatoma 22a growth]
Carcinoma, Renal Cell
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
Cardiomegaly
AKAP signaling complexes: getting to the heart of the matter.
Cardiomyopathy, Restrictive
Epigenetic regulation of phosphodiesterase 4d in restrictive cardiomyopathy mice with cTnI mutations.
Cardiovascular Diseases
Candidate gene analysis in the São Paulo Epidemiologic Sleep Study (EPISONO) shows an association of variant in PDE4D and sleepiness.
Inhibition of PDE4 by low doses of rolipram induces changes in lipid and protein components of mice heart.
Carotid Artery Diseases
Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
Carotid Artery Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Central Nervous System Diseases
Phosphodiesterase Type 4 Inhibition in CNS Diseases.
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Cerebral Infarction
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Correlation between the single nucleotide polymorphisms of the human phosphodiesterase 4D gene and the risk of cerebral infarction in the Uygur and Han ethnic groups of Xinjiang, China.
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Cerebrovascular Disorders
Association between PDE4D gene and ischemic stroke: recent advancements.
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.
Cholera
Characterization of the yeast low Km cAMP-phosphodiesterase with cAMP analogues. Applications in mammalian cells that express the yeast PDE2 gene.
Cyclic AMP responses are suppressed in mammalian cells expressing the yeast low Km cAMP-phosphodiesterase gene.
Decreased phosphodiesterase activity in cholera toxin-induced hypersecretion in suckling rats.
Cholestasis
Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP.
Chorioamnionitis
Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits.
Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
Colitis
Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis.
The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice.
Colitis, Ulcerative
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients with Active Ulcerative Colitis.
Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Tetomilast.
Colonic Neoplasms
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.
Colorectal Neoplasms
Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway.
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture.
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.
Coronary Disease
Features of coronary heart disease development in emergency workers of the Chornobyl accident depending on the action of radiation and non radiation risk factors and genotypes of single nucleotide polymorphism rs966221 of phosphodiesterase 4D gene.
GENDER DISPARITIES OF CIRCULATORY DISEASE PROGRESS IN THE CHORNOBYL ACCIDENT CLEAN-UP WORKERS AND PHOSPHODIESTERASE 4D GENE rs966221 POLYMORPHISM.
Structural and functional state of heart left ventricle depending on polymorphism rs966221 phosphodiesterase 4D gene in emergency workers of the Chornobyl NPP suffering from coronary heart disease.
Cough
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Effects of phosphodiesterase 4 inhibitor on cough response in guinea pigs sensitized and challenged with ovalbumin.
COVID-19
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients.
PdCl2-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor.
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
Cryptorchidism
Expression of Phosphodiesterase 4B cAMP-Specific Gene in Subjects With Cryptorchidism and Down's Syndrome.
Surgically induced cryptorchidism-related degenerative changes in spermatogonia are associated with loss of cyclic adenosine monophosphate-dependent phosphodiesterases type 4 in abdominal testes of rats.
Cystitis
Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats.
Cysts
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.
Dementia
Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia.
Demyelinating Diseases
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Dermatitis
Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNF-alpha level and ameliorates skin edema in phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation model in mice.
AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis.
Imperatorin Alleviates Psoriasiform Dermatitis by Blocking Neutrophil Respiratory Burst, Adhesion, and Chemotaxis Through Selective Phosphodiesterase 4 Inhibition.
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Dermatitis, Allergic Contact
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Effects of cilomilast on dendritic cell function in contact sensitivity and dendritic cell migration through skin.
Dermatitis, Atopic
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
A dried blood spot assay with UPLC-MS/MS for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human blood.
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults.
Advances in the understanding and treatment of atopic dermatitis.
An assessment of the genetic toxicology of novel boron-containing therapeutic agents.
Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Application of phosphodiesterase 4 inhibitor for atopic dermatitis.
Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis.
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Cyclic AMP-phosphodiesterase activity and histamine release in cord blood leukocyte preparations.
Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double-blind, vehicle-controlled trial.
Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line.
Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study.
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
Histamine up-regulates phosphodiesterase IV activity in U-937 cells through H2 receptor stimulation and cAMP increase.
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
In Vitro Skin Retention of Crisaborole after Topical Application.
Intracellular 3',5'-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis.
Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Off-Label Therapeutic Potential of Crisaborole.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Phosphodiesterase 4D, miR-203 and selected cytokines in the peripheral blood are associated with canine atopic dermatitis.
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to?
Soft drugs for dermatological applications: recent trends.
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis.
Topical Agents for the Treatment of Atopic Dermatitis
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Treatment of psoriasis with crisaborole.
Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma.
[What's new in pediatric dermatology?]
Dermatitis, Phototoxic
Phosphodiesterase 4B plays a role in benzophenone-3-induced phototoxicity in normal human keratinocytes.
Diabetes Insipidus, Nephrogenic
Dynamics of nucleotides in distal nephron of mice with nephrogenic diabetes insipidus.
Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus.
Diabetes Mellitus
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Diabetes Mellitus, Type 1
An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients.
Diabetes Mellitus, Type 2
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Diabetic Nephropathies
Protective effect of a novel phosphodiesterase 4 selective inhibitor, compound A, in diabetic nephropathy model mice.
Diabetic Neuropathies
Low concentration of Bupivacaine ameliorates painful diabetic neuropathy by mediating miR-23a/PDE4B axis in microglia.
Disorders of Excessive Somnolence
Erratum to "The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease" [Park. Relat. Disord. 77C (2021) 163-169/3948].
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.
Down Syndrome
Expression of Phosphodiesterase 4B cAMP-Specific Gene in Subjects With Cryptorchidism and Down's Syndrome.
Dyslexia
A Cohort of Balanced Reciprocal Translocations Associated with Dyslexia: Identification of Two Putative Candidate Genes at DYX1.
Dyspnea
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Ectropion
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
Embolic Stroke
Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.
Encephalomyelitis
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis.
Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse.
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis.
Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse.
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis.
Endometrial Neoplasms
The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
Endotoxemia
Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.
Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation.
Rolipram Attenuates Bile Duct Ligation-Induced Liver Injury in Rats: A Potential Pathogenic Role of PDE4.
Eosinophilia
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Epilepsy
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study.
Erectile Dysfunction
Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.
Fetal Alcohol Spectrum Disorders
Phosphodiesterase type 4 inhibition does not restore ocular dominance plasticity in a ferret model of fetal alcohol spectrum disorders.
Fetal Death
PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation.
Fibrosarcoma
Enhancement of the relative uptake of 18F-FDG in mouse fibrosarcoma by rolipram.
Fibrous Dysplasia, Polyostotic
PET imaging of phosphodiesterase-4 identifies affected dysplastic bone in McCune-Albright syndrome, a genetic mosaic disorder.
Fragile X Syndrome
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Gastroparesis
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
Glioblastoma
Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
The Role of Protein Kinase B Signaling Pathway in Anti-Cancer Effect of Rolipram on Glioblastoma Multiforme: An In Vitro Study.
Theobromine, the Primary Methylxanthine Found in Theobroma cacao, Prevents Malignant Glioblastoma Proliferation by Negatively Regulating Phosphodiesterase-4, Extracellular Signal-regulated Kinase, Akt/mammalian Target of Rapamycin Kinase, and Nuclear Factor-Kappa B.
Glioma
Adsorption of miR-218 by lncRNA HOTAIR regulates PDE7A and affects glioma cell proliferation, invasion, and apoptosis.
BDNF and PDE4, but not the GRPR, Regulate Viability of Human Medulloblastoma Cells.
Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Intracranial glioma xenograft model rapidly reestablishes blood-brain barrier integrity for longitudinal imaging of tumor progression using fluorescence molecular tomography and contrast agents.
Graft vs Host Disease
Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice.
Erratum to "Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice".
Granuloma
Selective Inhibition of PDE4 in Wistar Rats Can Lead to Dilatation in Testis, Efferent Ducts, and Epididymis and Subsequent Formation of Sperm Granulomas.
Growth Hormone-Secreting Pituitary Adenoma
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Head and Neck Neoplasms
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Hearing Loss, Sensorineural
Phosphodiesterase 4D gene polymorphisms in sudden sensorineural hearing loss.
Heart Failure
Cardiac Overexpression of PDE4B Blunts ?-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Phosphodiesterase 4D and heart failure: a cautionary tale.
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Hematologic Neoplasms
PDE4 subtypes in cancer.
Hemoglobinopathies
Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in ?-Thalassemia Intermedia: A Validation Cohort Study.
Hemorrhagic Stroke
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Hepatitis
Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice.
Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis.
Hepatitis, Autoimmune
PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.
Herpes Simplex
Methodology and problems of protein-ligand docking: case study of dihydroorotate dehydrogenase, thymidine kinase, and phosphodiesterase 4.
Herpes Zoster
Studies on cyclic nucleotides in the adrenal gland. VIII. Effects of angiotensin on adenosine 3',5'-monophosphate and steroidogenesis in the adrenal cortex.
HIV Infections
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
Huntington Disease
Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.
Hyperalgesia
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion.
Hypercalcemia
AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Hypersensitivity
Neonatal leukocyte cAMP-phosphodiesterase determination is not suitable for allergy prediction.
Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction.
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Hypertension
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model.
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.
Regulation of renovascular adenosine 3',5'-cyclic monophosphate in spontaneously hypertensive rats.
Hypertension, Pulmonary
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor on Hypoxia- and Monocrotaline-induced Pulmonary Hypertension in Rats.
Hyperthyroidism
Influence of exogenous ATP on blood sugar, serum insulin and serum free fatty acids in short-term experimental hyperthyroid dogs and in euthyroid controls.
Hypophosphatemia, Familial
Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo.
Hypothyroidism
Low particulate type IV phosphodiesterase activity in hypothyroid rat atria.
Idiopathic Pulmonary Fibrosis
Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
Infarction, Middle Cerebral Artery
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Infections
Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.
Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits.
Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update.
cAMP-specific phosphodiesterase TbPDE1 is not essential in Trypanosoma brucei in culture or during midgut infection of tsetse flies.
Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4.
Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells.
Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication.
Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.
The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence.
[Acute exacerbation in COPD and asthma].
Infertility, Female
Conditional rescue of the dunce learning/memory and female fertility defects with Drosophila or rat transgenes.
Inflammatory Bowel Diseases
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Tetomilast: new promise for phosphodiesterase-4 inhibitors?
TGF-? activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Insulin Resistance
Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.
Insulinoma
PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C.
Intracranial Aneurysm
[Genetics of cerebral vascular accidents]
Ischemic Stroke
A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene.
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis.
Association between phosphodiesterase 4D gene and ischaemic stroke.
Association between phosphodiesterase 4D polymorphism SNP83 and ischemic stroke.
Association of a Genetic Variant in the ALOX5AP with Higher Risk of Ischemic Stroke: A Case-Control, Meta-Analysis and Functional Study.
Association of PDE4D and IL-1 gene polymorphism with ischemic stroke in a Han Chinese population.
Association of phosphodiesterase 4D gene and interleukin-6 receptor gene polymorphisms with ischemic stroke in a Chinese hypertensive population.
Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population.
Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population.
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Association of Phosphodiesterase 4D with ischemic stroke: a population-based case-control study.
Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.
Effects of PDE4 pathway inhibition in rat experimental stroke.
Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.
FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3?/ ?-catenin signaling pathway.
Genetic variants of phosphodiesterase 4D gene are associated with an enhanced risk for ischemic stroke in young Chinese population.
Genetics of ischemic stroke.
Impact of the PDE4D gene polymorphism and additional SNP-SNP and gene-smoking interaction on ischemic stroke risk in Chinese Han population.
Independent ischemic stroke risk factors in older Americans: a systematic review.
Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region.
Ischemic stroke risk in a southeastern Chinese population: Insights from 5-lipoxygenase activating protein and phosphodiesterase 4D single-nucleotide polymorphisms.
Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations.
No Association Between Single-Nucleotide Polymorphism 56 (SNP56) in Phosphodiesterase 4D (PDE4D) Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies.
Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke.
Phosphodiesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian population.
Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians.
Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.
Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population.
Phosphodiesterase 4D gene polymorphisms in sudden sensorineural hearing loss.
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke.
Phosphodiesterase4D (PDE4D)--A risk factor for atrial fibrillation and stroke?
Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.
Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation.
Relationship of phosphodiesterase 4D (PDE4D) gene polymorphisms with risk of ischemic stroke: a hospital based case-control study.
Rolipram stimulates angiogenesis and attenuates neuronal apoptosis through the cAMP/cAMP-responsive element binding protein pathway following ischemic stroke in rats.
Sex-dependent association of phosphodiesterase 4D gene polymorphisms with ischemic stroke in Henan Han population.
Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke.
The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
The phosphodiesterase 4D gene for early onset ischemic stroke among normotensive patients.
The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
The Siblings With Ischemic Stroke Study (SWISS): A Progress Report.
Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?
[Analysis of the polymorphic variants of the PDE4D gene in patients with acute stroke in the Moldavian population].
 Investigation of single nucleotide polymorphisms in phosphodiesterase 4D gene in Mongol and Han patients with ischemic stroke in Inner Mongolia.
Kidney Diseases
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Kidney Diseases, Cystic
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.
Kidney Neoplasms
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
Latent Autoimmune Diabetes in Adults
An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients.
Learning Disabilities
New Selective Phosphodiesterase 4D Inhibitors Differently Acting on Long, Short, and Supershort Isoforms.
Leukemia
Bresol inhibits phosphodiesterase 4 gene expression and modulates the levels of select mediators of inflammation in human monocytic cells.
Synergistic effect of caffeine and glucocorticoids on expression of surfactant protein B (SP-B) mRNA.
Systematic identification of regulatory variants associated with cancer risk.
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.
Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.
Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Leukemia, Myeloid, Acute
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Lichen Planus, Oral
Expression and significance of phosphodiesterase 4B gene in peripheral blood of patients with oral lichen planus.
Liver Cirrhosis
Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition.
Liver Diseases, Alcoholic
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease.
Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
Lung Diseases
Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts.
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor.
Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Phosphodiesterase-4 inhibitor therapy for lung diseases.
Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge.
Lung Diseases, Obstructive
A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
Investigating the role of N-terminal domain in phosphodiesterase 4B-inhibition by molecular dynamics simulation.
[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease]
Lung Injury
Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.
Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs.
Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.
Osthol attenuates neutrophilic oxidative stress and hemorrhagic shock-induced lung injury via inhibition of phosphodiesterase 4.
Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Suppression of neutrophilic inflammation can be modulated by the droplet size of anti-inflammatory nanoemulsions.
Use of a Soluble Epoxide Hydrolase Inhibitor in Smoke-Induced Chronic Obstructive Pulmonary Disease.
Lung Neoplasms
PDE4 subtypes in cancer.
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Lymphoma
Cyclic adenosine monophosphate signal pathway in targeted therapy of lymphoma.
Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.
MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
[Expression of Cyclic Nucleotide Phosphodiesterase 7B in Patients with Mantle Cell Lymphoma and Its Prognostic Significance.]
Lymphoma, B-Cell
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Lymphoma, Mantle-Cell
High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.
[Expression of Cyclic Nucleotide Phosphodiesterase 7B in Patients with Mantle Cell Lymphoma and Its Prognostic Significance.]
Medulloblastoma
Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma.
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Melanoma
A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.
Activation of ?2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.
Debenzylative Cycloetherification as a Synthetic Tool in the Diastereoselective Synthesis of 3,6-Disubstituted Hexahydro-2H-furo[3,2-b]pyrroles, PDE1 Enzyme Inhibitors with an Antiproliferative Effect on Melanoma Cells.
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
Phosphodiesterase 4 regulates the migration of B16-F10 melanoma cells.
Memory Disorders
Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System.
Inhibiting PDE7A Enhances the Protective Effects of Neural Stem Cells on Neurodegeneration and Memory Deficits in Sevoflurane-Exposed Mice.
Inhibition of phosphodiesterase-4 reverses memory deficits produced by A?25-35 or A?1-40 peptide in rats.
Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats.
Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease.
RNA Interference-Mediated Knockdown of Long-Form Phosphodiesterase-4D (PDE4D) Enzyme Reverses Amyloid-?42-Induced Memory Deficits in Mice.
Rolipram rescues memory consolidation deficits caused by sleep deprivation: Implication of the cAMP/PKA and cAMP/Epac pathways.
The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss.
The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer's disease: a preclinical study in APP/PS1 transgenic mice.
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
Metabolic Diseases
Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases.
Mouth Neoplasms
Ligand/PTC-free intramolecular Heck reaction: synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo.
Multiple Sclerosis
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis.
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Muscular Atrophy
Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy.
Phosphodiesterase 4B knockout prevents skeletal muscle atrophy in rats with burn injury.
Muscular Dystrophy, Duchenne
Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Myelodysplastic Syndromes
CC-1088 Celgene.
Myocardial Infarction
A haplotype of the phosphodiesterase 4D (PDE4D) gene is associated with myocardial infarction and with cardiometabolic parameters: the GEA study.
Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
[Association of rs966221 phosphodiesterase 4D gene's polymorphism with risk of myocardial infarction].
Myoclonus
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study.
Myoma
[Effect of 17 beta-estradiol on 3',5'-cyclic AMP phosphodiesterase of uterine tissues in myoma]
Myopia
Declines in PDE4B activity promote myopia progression through downregulation of scleral collagen expression.
Nasopharyngeal Carcinoma
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Neoplasm Metastasis
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
Neoplasms
7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells.
A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity.
Advances in the Development of Phosphodiesterase-4 Inhibitors.
Apremilast and its role in psoriatic arthritis.
Apremilast in dermatology: A review of literature.
Attenuation of cAMP-mediated responses in MA-10 Leydig tumor cells by genetic manipulation of a cAMP-phosphodiesterase.
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Candidate gene analysis in the São Paulo Epidemiologic Sleep Study (EPISONO) shows an association of variant in PDE4D and sleepiness.
Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.
Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Correction: Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells.
Cyclic AMP-binding proteins: inverse relationship with estrogen-receptors in hormone-dependent mammary tumor regression.
Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Enhancement of the relative uptake of 18F-FDG in mouse fibrosarcoma by rolipram.
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.
Gene expression changes in peripheral blood mononuclear cells during measles virus infection.
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells.
Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma.
H-Prune through GSK-3? interaction sustains canonical WNT/?-catenin signaling enhancing cancer progression in NSCLC.
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Identification of Gene Loci That Overlap Between Mental Disorders and Poor Prognosis of Cancers.
Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation.
Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Intracranial glioma xenograft model rapidly reestablishes blood-brain barrier integrity for longitudinal imaging of tumor progression using fluorescence molecular tomography and contrast agents.
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.
Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells.
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.
PDE4 subtypes in cancer.
PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.
PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.
Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane.
Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.
Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Phosphodiesterase sequence variants may predispose to prostate cancer.
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Plasma cAMP and cAMP-phosphodiesterase (PDE) levels in cancer patients before and after surgery.
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Quinolines: a new hope against inflammation.
Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
Rolipram Attenuates Bile Duct Ligation-Induced Liver Injury in Rats: A Potential Pathogenic Role of PDE4.
Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B cell malignancies.
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation.
Signaling of the direction-sensing FAK/RACK1/PDE4D5 complex to the small GTPase Rap1.
siRNA-mediated silencing of phosphodiesterase 4B expression affects the production of cytokines in endotoxin-stimulated primary cultured microglia.
Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.
Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.
Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.
Systematic identification of regulatory variants associated with cancer risk.
Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon.
The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.
The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide.
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between Tumor necrosis factor-alpha and interleukin-10.
The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Therapy for chronic obstructive pulmonary disease in the 21st century.
Tilapia hepcidin 2-3 peptide modulates lipopolysaccharide-induced cytokines and inhibits tumor necrosis factor-alpha through cyclooxygenase-2 and phosphodiesterase 4D.
Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
Triazole-Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells.
Tumor Necrosis Factor ? as a Potential Mediator of the Effects of Phosphodiesterase 4B Inhibition on Cognition after Traumatic Brain Injury.
Unconventional therapies for hidradenitis suppurativa.
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Nervous System Diseases
Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders.
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
PDE4 Inhibition by Rolipram Promotes Neuronal Differentiation in Human Bone Marrow Mesenchymal Stem Cells.
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Rapid identification of a novel phosphodiesterase 7B tracer for receptor occupancy studies using LC?MS/MS.
Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, A? extrusion transporter ABCB1, and reversal by PKA inhibitor H89.
Neuralgia
Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation.
Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion.
The Analgesic Effect of Rolipram, a Phosphodiesterase 4 Inhibitor, on Chemotherapy-Induced Neuropathic Pain in Rats.
Neurobehavioral Manifestations
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Neuroblastoma
Induction and quantitation of the RI cAMP-binding protein in clonal mouse neuroblastoma cell lines: evidence that the increase in RI is not linked to neurite outgrowth.
Specificity of the action of cAMP agonists in the induction of RI cAMP-binding protein in mouse neuroblastoma cells.
Neurodegenerative Diseases
Development of improved models for phosphodiesterase-4 inhibitors with a multi-conformational structure-based QSAR method.
Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease.
Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid.
Neuroinflammatory Diseases
Lipopolysaccharide administration in vivo induces differential expression of cAMP-specific phosphodiesterase 4B mRNA splice variants in the mouse brain.
Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF-?B Inhibition.
Overexpression of phosphodiesterase-4 subtypes involved in surgery-induced neuroinflammation and cognitive dysfunction in mice.
PDE4B as a microglia target to reduce neuroinflammation.
Phosphodiesterase 4B: Master Regulator of Brain Signaling.
Neuronal Ceroid-Lipofuscinoses
Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
Non-alcoholic Fatty Liver Disease
Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients with Nonalcoholic Steatohepatitis.
Obesity
Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity.
Analyses of shared genetic factors between asthma and obesity in children.
Molecular characterization of an interstitial deletion of 1p31.3 in a patient with obesity and psychiatric illness and a review of the literature.
Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.
Theobromine alleviates diet-induced obesity in mice via phosphodiesterase-4 inhibition.
Obstetric Labor, Premature
Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3',5'-monophosphate-dependent pathway.
Uterus-relaxing effect of ?(2) -agonists in combination with phosphodiesterase inhibitors: Studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
Oral Ulcer
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Apremilast in the Management of Disseminated Granuloma Annulare.
Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Osteoarthritis
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
Osteosarcoma
Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition.
Parkinson Disease
Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP
Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson's disease.
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Phosphodiesterase 4: Rethinking cognition in Parkinson disease.
Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.
Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease.
Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease.
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.
Pemphigoid, Bullous
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
Pemphigus
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
Peripheral Vascular Diseases
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Peritonitis
Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.
Pituitary Neoplasms
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Pityriasis
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
Pityriasis Rubra Pilaris
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
Pneumonia
Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency.
An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.
Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
G Protein ??-Subunit Signaling Mediates Airway Hyperresponsiveness and Inflammation in Allergic Asthma.
Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and atopy.
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Roflumilast: A Review in COPD.
The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs.
The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Polycystic Ovary Syndrome
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Phosphodiesterase 4 inhibitor plus metformin is superior to metformin alone for the treatment of polycystic ovary syndrome: A rat model study.
Polydactyly
Elevated rate of DNA synthesis and its correlation to cAMP-phosphodiesterase activity during induction of polydactyly in mouse embryos heterozygous for Hemimelia-extra toe (Hmx).
Polyuria
AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Low aquaporin-2 levels in polyuric DI +/+ severe mice with constitutively high cAMP-phosphodiesterase activity.
Prolactinoma
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Prostatic Neoplasms
Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.
Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance.
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.
The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Proteinuria
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.
Pruritus
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Psoriasis
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
Apremilast ameliorates IL-1?-induced dysfunction in epidermal stem cells.
Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6.
Apremilast and suicidality: a retrospective analysis of three large databases: the FAERS, EudraVigilance, and a large single-center U.S. patient population.
Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic.
Apremilast for psoriasis treatment.
Apremilast for the management of moderate to severe plaque psoriasis.
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
Apremilast in psoriasis - a prospective real-world study.
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
Apremilast in Refractory Alopecia Areata.
Apremilast in the Management of Disseminated Granuloma Annulare.
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.
Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.
Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
CC-10004 .
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial.
Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study.
Development of alopecia areata during phosphodiesterase 4 inhibitor treatment for psoriasis: A case report.
Drug survival of apremilast in a real-world setting.
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.
Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.
Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.
Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis.
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
New and emerging therapies in psoriasis.
New Oral Therapies for Psoriasis: A Comprehensive Review.
New Therapies for Psoriasis.
Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Novel systemic therapies for the treatment of psoriasis.
Off-label studies on apremilast in dermatology: a review.
Oral Apremilast for the Treatment of Plaque Psoriasis.
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study.
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Phosphodiesterase-4 Inhibition in Psoriasis.
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
Positioning of apremilast in treatment of Behçet's disease.
Real-World Experience With Apremilast in Treating Psoriasis.
Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
Real-world use of apremilast for patients with psoriasis in Japan.
Refractory palmoplantar pustulosis succesfully treated with apremilast.
Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis.
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Targeted Therapy for Pediatric Psoriasis.
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
The Protective Effects of Apremilast Against Oxygen-Glucose Deprivation/Reperfusion (OGD/R)-Induced Inflammation and Apoptosis in Astroglia Mediated by CREB/BDNF.
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.
Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
[Gastrointestinal side effects of apremilast : Characterization and management].
Pulmonary Arterial Hypertension
Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model.
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.
Pulmonary Disease, Chronic Obstructive
(P)/(M)-corinepalensin A, a pair of axially chiral prenylated bicoumarin enantiomers with a rare C-5C-5' linkage from the twigs of Coriaria nepalensis.
3,4,5-Trihydroxycinnamic acid exerts a protective effect on pulmonary inflammation in an experimental animal model of COPD.
3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
A Novel Heterodimer from Crotalaria ferruginea.
Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats.
ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.
Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells.
Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Analysis of the polarization states of the alveolar macrophages in chronic obstructive pulmonary disease samples based on miRNA-mRNA network signatures.
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.
Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism.
Benefits and harms of roflumilast in moderate to severe COPD.
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation.
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Cardiovascular Safety In Patients Receiving Roflumilast for the Treatment of Chronic Obstructive Pulmonary Disease.
CC-10004 .
Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model.
Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.
Chronic obstructive pulmonary disease: emerging therapies.
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Cilomilast GlaxoSmithKline.
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.
Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Common lung conditions: chronic obstructive pulmonary disease.
Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.
COPD: current therapeutic interventions and future approaches.
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Cross-talk between PKA-C? and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Current and emerging therapies for the management of chronic inflammation in asthma.
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.
Cytokines as targets in chronic obstructive pulmonary disease.
Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study.
Development of improved models for phosphodiesterase-4 inhibitors with a multi-conformational structure-based QSAR method.
Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.
Direct Inhibitory Effect of the Phosphodiesterase-4 Inhibitor, Roflumilast, on Neutrophil Migration in COPD.
Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor.
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study.
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
Effect of roflumilast on airway remodelling in a murine model of chronic asthma.
Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide.
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis.
Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Efficacy and safety of roflumilast in the treatment of asthma.
Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
Efficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysis.
Electrochemical Behavior and Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms.
Emerging drugs for the treatment of chronic obstructive pulmonary disease.
Emerging targets for COPD therapy.
Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease.
Future treatment of chronic obstructive pulmonary disease.
Future treatments for chronic obstructive pulmonary disease and its comorbidities.
Glucocorticoid Receptor ? Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
GS-5759, a Bifunctional ?2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells.
How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study.
Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages.
Is there a role for antiinflammatory treatment in COPD?
Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey.
Lysoquinone-TH1, a New Polyphenolic Tridecaketide Produced by Expressing the Lysolipin Minimal PKS II in Streptomyces albus.
Mini Review: Chronic obstructive pulmonary disease, its new drug treatments and strategies: A review.
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.
Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease.
No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine.
No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
Novel signal transduction modulators for the treatment of airway diseases.
Optimal treatment sequence in COPD: Can a consensus be found?
Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators".
PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1.
PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease.
Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Pharmacology of a novel, orally active PDE4 inhibitor.
Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors.
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Phosphodiesterase 4 inhibitors for the treatment of COPD.
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease.
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.
Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Phosphodiesterase-4 inhibition in COPD.
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).
Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease.
Piclamilast inhibits the pro-apoptotic and anti-proliferative responses of A549 cells exposed to H(2)O(2) via mechanisms involving AP-1 activation.
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases.
Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from Toddalia asiatica.
Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Production and characterization of pharmacologically active recombinant human phosphodiesterase 4B in Dictyostelium discoideum.
Prospects for new drugs for chronic obstructive pulmonary disease.
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.
Psiguajadials A-K: Unusual Psidium Meroterpenoids as Phosphodiesterase-4 Inhibitors from the Leaves of Psidium guajava.
Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease.
Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Roflumilast - a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes via the CREB/BDNF Signaling Pathway.
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
Roflumilast for asthma: Efficacy findings in mechanism of action studies.
Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.
Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies.
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection.
Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-? and Chemokine Production by Human Lung Parenchyma.
Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells.
Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Roflumilast Reduced the IL-18-Induced Inflammatory Response in Fibroblast-Like Synoviocytes (FLS).
Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.
Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
Roflumilast with long-acting {beta}2 agonists for COPD: influence of exacerbation history.
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Roflumilast: A Review in COPD.
Roflumilast: a review of its use in the treatment of COPD.
Roflumilast: clinical benefit in patients suffering from COPD.
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Roflumilast: in chronic obstructive pulmonary disease.
Roflumilast: systemic therapy for chronic obstructive pulmonary disease.
Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease.
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.
Selaginpulvilins A-D, new phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella pulvinata.
Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences.
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
Structure Based Design of Selective Phosphodiesterase 4B Inhibitors Based on Ginger Phenolic Compounds.
Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Targeting lung inflammation: novel therapies for the treatment of COPD.
Tetomilast.
Tetomilast: new promise for phosphodiesterase-4 inhibitors?
The airway pathophysiology of COPD: implications for treatment.
The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting ?2-adrenoceptor agonist.
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
The pharmacological approach to the elderly COPD patient.
The phosphodiesterase 4 inhibitor rolipram protects against cigarette smoke extract-induced apoptosis in human lung fibroblasts.
The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys.
The use of roflumilast in COPD: a primary care perspective.
Therapeutic options for chronic obstructive pulmonary disease: present and future.
Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
Treatments for COPD.
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.
Vulnerable COPD patients with comorbidities: the role of roflumilast.
Warfarin pharmacodynamics unaffected by cilomilast.
[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].
[Acute exacerbation in COPD and asthma].
[Clinical profile of roflumilast].
[New treatments for chronic obstructive pulmonary disease]
[Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
[Pharmacological profile of roflumilast].
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
[Prevention of acute exacerbation of chronic obstructive pulmonary disease].
[Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD]
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD]
{blacktriangledown}Roflumilast for severe COPD?
Pulmonary Eosinophilia
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.
Pulmonary Fibrosis
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
Pyelonephritis
Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats.
Reperfusion Injury
Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Transcription Factor Trps1 Promotes Tubular Cell Proliferation after Ischemia-Reperfusion Injury through cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D and AKT.
Respiratory Distress Syndrome
Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis.
Respiratory Insufficiency
Inhibition of protein kinase A and GIRK channel reverses fentanyl-induced respiratory depression.
Reversal by phosphodiesterase-4 blockers of in vitro apnea in the isolated brainstem-spinal cord preparation from newborn rats.
Rhinitis, Allergic
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.
Inhibition of phosphodiesterase 4 in allergic rhinitis.
New therapies for allergic rhinitis.
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
Rubinstein-Taybi Syndrome
A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4.
Sarcoma
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture.
Scleroderma, Systemic
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Sepsis
Circ_0091702 relieves lipopolysaccharide (LPS)-induced cell injury by regulating the miR-182/PDE7A axis in sepsis.
Cyclic adenosine monophosphate-phosphodiesterase inhibitors reduce skeletal muscle protein catabolism in septic rats.
Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Roflumilast as a Potential Therapeutic Agent for Cecal Ligation and Puncture-Induced Septic Lung Injury.
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
Shock, Septic
Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.
Skin Diseases
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity.
Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Sleep Deprivation
Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.
Rolipram rescues memory consolidation deficits caused by sleep deprivation: Implication of the cAMP/PKA and cAMP/Epac pathways.
Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1.
Sleep deprivation impairs cAMP signalling in the hippocampus.
Spasm
Coronary vasodilatory, spasmolytic and cAMP-phosphodiesterase inhibitory properties of dihydropyranocoumarins and dihydrofuranocoumarins.
Spermatic Cord Torsion
Beneficial effects of rolipram, a phosphodiesterase 4 specific inhibitor, on testicular torsion-detorsion injury in rats.
Spinal Cord Injuries
A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes and tissue damage after spinal cord injury.
Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.
Meglumine cyclic adenylate improves neurological function following acute spinal cord injury in rats.
Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury.
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.
Spondylitis, Ankylosing
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Starvation
DdPDE4, a novel cAMP-specific phosphodiesterase at the surface of dictyostelium cells.
Developmental regulation of the cyclic-nucleotide-phosphodiesterase mRNA of Dictyostelium discoideum. Analysis by cell-free translation and immunoprecipitation.
Stroke
ALOX5AP gene and the PDE4D gene in a central European population of stroke patients.
Association between PDE4D gene and ischemic stroke: recent advancements.
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Association of SNP41, SNP56 and a novel SNP in PDE4D gene with stroke and its subtypes.
Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.
Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.
Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.
Genes contributing to risk for common forms of stroke.
Genetics of ischemic stroke: An Indian scenario.
Genome-wide linkage scan of common stroke in families from northern Sweden.
Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control study design (Study protocol).
In silico pharmacology suggests ginger extracts may reduce stroke risks.
Meta-Analysis of Homogeneous Subgroups Reveals Association between PDE4D Gene Variants and Ischemic Stroke.
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
PDE4 Regulates Tissue Plasminogen Activator Expression of Human Brain Microvascular Endothelial Cells.
Phosphodiesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian population.
Phosphodiesterase 4D gene polymorphism is associated with ischaemic and haemorrhagic stroke.
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Phosphodiesterase 4D Single Nucleotide Polymorphism 83 and Cognitive Dysfunction in Carotid Endarterectomy Patients.
Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
Stroke genetics--focus on PDE4D gene.
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target.
[Association of cerebral stroke with a phosphodiesterase 4D (PDE4D) gene polymorphism in the Moscow population].
[Phosphodiesterase 4D (PDE4D) gene polymorphism in patients with acute stroke from Moscow]
Stupor
Role of phosphodiesterase-4 on ethanol elicited locomotion and narcosis.
Subarachnoid Hemorrhage
Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway.
Tachycardia
Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.
Tardive Dyskinesia
Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Independent ischemic stroke risk factors in older Americans: a systematic review.
The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
Thyroid Neoplasms
Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.
Trypanosomiasis, African
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors.
Discovery of Diaryl Ether Substituted Tetrahydrophthalazinones as TbrPDEB1 Inhibitors Following Structure-Based Virtual Screening.
Discovery of Novel Trypanosoma brucei Phosphodiesterase B1 Inhibitors by Virtual Screening against the Unliganded TbrPDEB1 Crystal Structure.
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Tuberculosis
A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE).
Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
Tuberculosis, Meningeal
Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.
Tuberculosis, Pulmonary
Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
unspecific monooxygenase deficiency
Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.
Urinary Bladder, Overactive
Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.
Vascular Diseases
Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population.
Vascular System Injuries
Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor.
Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog.
Effects of modulating in vivo nitric oxide production on the incidence and severity of PDE4 inhibitor-induced vascular injury in sprague-dawley rats.
PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.
Vasculitis
Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor.
Ventricular Dysfunction, Left
Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting.
Virus Diseases
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Vitiligo
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.